Alabama Clinical Trials Report — July 2026

Alabama residents who may qualify for a clinical trial should act now if they are considering a study that could close soon. 57 recruiting trials are expected to close within the next 90 days, including 10 that accept healthy volunteers. Screening can take time, and projected closing dates may change, so contacting a study site promptly is the best way to preserve an opportunity.

At the same time, Alabama has 1,214 trials recruiting across 38 cities and 584 research sites. The state added 21 new trials in July, down from 26 in both May and June. The monthly pattern has fluctuated, rising from 20 new trials in February to 34 in March, then easing to 29 in April, 26 in May and June, and 21 in July. The data also show 4 new trials listed for August, suggesting that the research pipeline may remain active but uneven.

Closing studies create a narrow window for several conditions

People with skin disease, blood cancers, prostate cancer, or orthopedic and vascular conditions make up some of the most visible groups among Alabama trials nearing closure. Atopic dermatitis leads with 3 closing-soon trials. Prostate cancer and multiple myeloma follow with 2 each.

• Atopic dermatitis — 3 trials closing within 90 days
• Prostate cancer — 2
• Multiple myeloma — 2
• Acute stress reaction, traumatic or surgical amputation, amputation wound, alveolar mucosa, arteriovenous fistula, hip arthritis, and knee arthritis — 1 each

The closing group is not limited to drug treatment. A person with a qualifying condition may find a medication study, procedure-focused study, device evaluation, or other type of research. Healthy volunteers should also search now: 10 of the 57 trials closing soon accept healthy participants, while 149 healthy-volunteer trials are recruiting statewide overall.

Enrollment status can change before the listed deadline. Prospective participants should review the eligibility requirements, confirm that the Alabama location is still enrolling, and ask how long screening will take before deciding whether to apply.

July brings major Phase 2 and Phase 3 opportunities

The strongest July additions include large drug and vaccine studies sponsored by Amgen, Sanofi, Novo Nordisk, and Axsome Therapeutics. These trials cover obesity, respiratory-virus prevention, and ADHD, while academic investigators are also testing approaches for chronic low back pain, cystic fibrosis, and advanced cancer.

• NCT07684235 — Amgen’s Phase 3 MARITIME-1-EXTENSION study evaluates the long-term efficacy, safety, and tolerability of maridebart cafraglutide in people with obesity or overweight. The extension plans to enroll 3,200 participants and follows an earlier study.
• NCT07734649 — Sanofi’s Phase 1/2 vaccine study examines an RSV and human metapneumovirus candidate in adults age 60 and older. It plans to enroll 2,400 participants and will evaluate immune response and safety.
• NCT07720271 — Novo Nordisk’s Phase 3 AMAZE 9 study evaluates once-daily zenagamtide tablets for people with excess body weight. The study plans to enroll 950 participants, who will receive either zenagamtide or placebo.
• NCT07717879 — Axsome Therapeutics’ Phase 3 study evaluates solriamfetol in children ages 6 to under 12 with ADHD. It plans to enroll 468 participants.
• NCT07717892 — A companion Axsome Phase 3 study evaluates solriamfetol in adolescents ages 12 to under 18 with ADHD, also targeting 468 participants.
• NCT07731256 — A Phase 2 Washington University study examines semaglutide for chronic low back pain, with 250 planned participants.
• NCT07723534 — A Phase 2 study evaluates zolbetuximab with chemotherapy regimens for advanced or metastatic biliary tract cancers in people whose tumors overexpress Claudin 18.2.

These studies give Alabama patients access to research involving established large sponsors and advanced development-stage medicines. The Amgen and Novo Nordisk studies may be especially relevant to people with overweight or obesity, while the two Axsome trials offer age-specific options for families seeking ADHD research. The Sanofi study stands out for adults 60 and older who may be interested in vaccine research.

Behavioral research leads the new-trial mix

July’s new studies are more varied than the headline drug trials suggest. Behavioral studies account for 9 of the 21 new openings, compared with 7 drug trials. Other interventions account for 4, while biological and device studies contribute 2 each and dietary supplements account for 1.

New research topics include overweight and obesity, cancer and cancer treatment, ADHD, anxiety, chronic lower back pain, allergic reactions, arthroscopic surgery, and child-adult interaction training. Two new trials address each of overweight, cancer, obesity, and ADHD. This range may give people more choices than traditional medication trials, including behavioral programs, procedures, devices, and other research approaches.

NCT07696338, “Rethinking Early Airway Clearance Therapies,” is one example of a nontraditional opportunity. The REACT trial includes two randomized studies involving hypertonic saline and dornase alfa for people with cystic fibrosis. Its planned enrollment is 405 participants.

Birmingham dominates, but opportunities reach communities statewide

Birmingham is the clear center of July’s new-trial activity, with 14 of the 21 new studies. Dothan follows with 2. Daphne, Gadsden, Homewood, Montgomery, Anniston, Tuscaloosa, and Auburn each have 1 new trial.

• Birmingham — 14 new trials
• Dothan — 2
• Daphne, Gadsden, Homewood, Montgomery, Anniston, Tuscaloosa, and Auburn — 1 each

The pattern shows a strong Birmingham concentration, consistent with the role of the University of Alabama at Birmingham in the state’s research network. However, new openings also appear across north, central, south, and southeastern Alabama. Residents outside Birmingham should search by city and travel distance rather than assuming every opportunity requires a trip to the state’s largest medical center.

Who should look for an opening this month?

Families should review the new listings carefully: 6 of July’s trials include children. One new study is female-only, and none are male-only. Older adults are included in 16 new trials, including the Sanofi RSV and human metapneumovirus vaccine study for people age 60 and older.

University of Alabama at Birmingham is the leading named sponsor, with 10 new trials. Axsome Therapeutics opened 2, while Auburn University, Midhun Malla, Nicole Hamblett, Novo Nordisk, Sanofi, and the University of Alabama in Tuscaloosa each sponsored 1. Overall, 15 new trials are classified as other rather than industry-sponsored, while 6 are industry-sponsored. This gives Alabama’s July research landscape a strong academic and local-institution presence alongside major pharmaceutical programs.

Patients with atopic dermatitis, prostate cancer, multiple myeloma, arthritis, or other conditions listed among the closing studies should begin inquiries immediately. Healthy adults, parents of children with ADHD, adults over 60, and people with overweight or obesity may find newly opened options, but availability is likely to change as sites complete screening. Through the rest of summer 2026, Alabama’s research opportunities are likely to keep shifting between concentrated Birmingham programs and smaller openings across the state.